Genomic examination and analysis for hereditary malignant tumors

Genomic examination and analysis for hereditary malignant tumors - Genomic examination and analysis for hereditary malignant tumors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011182

Enrollment

200

Registered

2013-07-12

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herediraty breast and ovarian cancer, Cowden disease, Li-fraumeni syndrome, familial adenomatous polyposis, hereditary non-poliposis colon cancer

Interventions

Genetic test for BRCA1 and BRCA2 mutations

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with suspected herediary malignand disease. 2. Relatives of patients with comfirmed hereditary malignant disease. 3. Healthy members of a pedigree of suspected hereditary malignant disease.

Exclusion criteria

Exclusion criteria: 1. Not enough for the criteria of the disease. 2. Client who doesn't receive pre-counseling. 3. Client younger than 20 y.o. 4. Client without a consent. 5. Client who cannot pay for the genetic test. 6. Client unsuitable for genetic test based on the ethical issue.

Design outcomes

Primary

Measure	Time frame
Efficacy of early detection program of hereditary cancers based on the results of genomic test	—

Countries

Japan

Contacts

Public ContactYasuhiro Tamaki

Osaka Medical Center for Cancer and Cardiovascular Diseases Breast and Endocrine Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026